Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL METABOLOMICS SERVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL METABOLOMICS SERVICES MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL METABOLOMICS SERVICES MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.3 KEY PRICING STRATEGIES
5.4 INTERVIEWS WITH SPECIALIST
5.5 OTHER KOL SNAPSHOTS
6 MERGERS AND ACQUISITION
6.1 LICENSING
6.2 COMMERCIALIZATION AGREEMENTS
7 REGULATORY FRAMEWORK
7.1 REGULATORY APPROVAL PROCESS
7.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
7.3 REGULATORY APPROVAL PATHWAYS
7.4 LICENSING AND REGISTRATION
7.5 POST-MARKETING SURVEILLANCE
7.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
8 R & D ANALYSIS
8.1 COMPARATIVE ANALYSIS
8.2 TECHNOLOGY DEVELOPMENTAL LANDSCAPE
8.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
8.4 THERAPEUTIC ASSESSMENT
8.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
9 MARKET OVERVIEW
9.1 DRIVERS
9.2 RESTRAINTS
9.3 OPPORTUNITIES
9.4 CHALLENGES
10 GLOBAL METABOLOMICS SERVICES MARKET , SWOT AND DBMR ANALYSIS
11 GLOBAL METABOLOMICS SERVICES MARKET, BY PRODUCT AND SERVICE PROVIDED
11.1 OVERVIEW
11.2 SAMPLE ANALYTICS SERVICE
11.2.1 TARGETED METABOLOMICS SERVICES
11.2.1.1. FATTY ACIDS
11.2.1.2. AMINO ACIDS
11.2.1.3. BILE ACID
11.2.1.4. HORMONES
11.2.1.5. CARBOHYDRATES
11.2.1.6. LIPIDS
11.2.1.7. OTHERS
11.2.2 UNTARGETED METABOLOMICS SERVICES
11.2.3 UNKNOWN METABOLITE IDENTIFICATION
11.2.4 METABOLITE IDENTIFICATION AND PROFILING
11.2.5 PHARMACOKINETIC STUDIES
11.2.6 DRUG-DRUG INTERACTION STUDIES
11.2.7 TOXICOLOGY ASSESSMENT
11.2.8 XENOBIOTIC METABOLITES ANALYSIS SERVICE
11.2.9 METABOLIC FLUX ANALYSIS (MFA) SERVICE
11.2.10 ICP-MS IONOMICS PROFILING SERVICE
11.2.11 OTHERS
11.3 DATA ANALYTICS AND BIOINFORMATICS SERVICE
11.3.1 ON SITE ANALYSIS
11.3.2 CLOUD BASED
11.4 OTHERS
12 GLOBAL METABOLOMICS SERVICES MARKET, BY METABOLOME PROFILING TECHNIQUE USED
12.1.1 SEPERATION TOOLS
12.1.1.1. GAS CHROMATOGRAPHY (GC)
12.1.1.2. LIQUID CHROMATOGRAPHY (LC)
12.1.1.3. CAPILLARY ELECTROPHORESIS (CE)
12.1.1.4. OTHERS
12.1.2 DETECTION TOOLS
12.1.2.1. MASS SPECTROMETRY
12.1.2.1.1. FOURIER TRANSFORM ION CYCLOTRON RESONANCES (FT-ICR-MS),
12.1.2.1.2. ORBITRAP MS
12.1.2.1.3. MULTIPASS TOF-M
12.1.2.1.4. SINGLE QUADRUPOLE MASS SPECTROMETER
12.1.2.1.5. OTHERS
12.1.2.2. NMR SPECTROSCOPY
12.1.3 OTHERS
13 GLOBAL METABOLOMICS SERVICES MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 MEDICAL AND PHARMACUITICAL
13.2.1 DRUG DEVELOPMNET
13.2.1.1. DRUG DISCOVERY
13.2.1.2. PRECINICAL CLINICAL STUDIES
13.2.1.3. OTHERS
13.2.2 BIOMARKER DISCOVERY
13.2.3 PERSONALIZED MEDICINE
13.2.4 TOXOLOGY TESTING
13.2.5 OTHERS
13.3 AGRICULTURE
13.3.1 PLANT METABOLOMICS
13.3.2 PESTICIDE ANALYSIS
13.3.3 OTHERS
13.4 ENVIRONMNET
13.5 FOOD INDUSTRY
13.5.1 NUTRIGENOMICS
13.5.2 OTHERS
13.6 BIOMEDICAL INDUSTRY
13.6.1 FUNCTIONAL GENOMICS
13.6.2 OTERS
13.7 OTHERS
14 GLOBAL METABOLOMICS SERVICES MARKET, BY INDICATION
14.1 OVERVIEW
14.2 CANCER
14.3 CARDIOVASCULAR DISORDERS (CVD)
14.4 NEUROLOGICAL DISORDERS
14.5 INBORN ERRORS OF METABOLISM
14.6 INFECTIOUS DISEASE
14.7 OTHERS
15 GLOBAL METABOLOMICS SERVICES MARKET, BY SAMPLE TYPE
15.1 HUMAN
15.1.1 URINE
15.1.2 BLOOD
15.1.3 FECAL
15.1.4 TUMOR
15.1.5 OTHERS
15.2 MICROBIAL
15.3 CELL CULTURE
15.4 OTHERS
16 GLOBAL METABOLOMICS SERVICES MARKET, BY END USERS
16.1 OVERVIEW
16.2 HOSPITALS
16.3 CLINICS
16.4 ACADEMICS AND RESEARCH INSTITUTE
16.5 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
16.6 OTHERS
17 GLOBAL METABOLOMICS SERVICES MARKET , COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL METABOLOMICS SERVICES MARKET , BY REGION
Global METABOLOMICS SERVICES market , (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
18.1 NORTH AMERICA
18.1.1 U.S.
18.1.2 CANADA
18.1.3 MEXICO
18.2 EUROPE
18.2.1 GERMANY
18.2.2 U.K.
18.2.3 ITALY
18.2.4 FRANCE
18.2.5 SPAIN
18.2.6 RUSSIA
18.2.7 SWITZERLAND
18.2.8 TURKEY
18.2.9 BELGIUM
18.2.10 NETHERLANDS
18.2.11 DENMARK
18.2.12 SWEDEN
18.2.13 POLAND
18.2.14 NORWAY
18.2.15 FINLAND
18.2.16 REST OF EUROPE
18.3 ASIA-PACIFIC
18.3.1 JAPAN
18.3.2 CHINA
18.3.3 SOUTH KOREA
18.3.4 INDIA
18.3.5 SINGAPORE
18.3.6 THAILAND
18.3.7 INDONESIA
18.3.8 MALAYSIA
18.3.9 PHILIPPINES
18.3.10 AUSTRALIA
18.3.11 NEW ZEALAND
18.3.12 VIETNAM
18.3.13 TAIWAN
18.3.14 REST OF ASIA-PACIFIC
18.4 SOUTH AMERICA
18.4.1 BRAZIL
18.4.2 ARGENTINA
18.4.3 REST OF SOUTH AMERICA
18.5 MIDDLE EAST AND AFRICA
18.5.1 SOUTH AFRICA
18.5.2 EGYPT
18.5.3 BAHRAIN
18.5.4 UNITED ARAB EMIRATES
18.5.5 KUWAIT
18.5.6 OMAN
18.5.7 QATAR
18.5.8 SAUDI ARABIA
18.5.9 REST OF MEA
18.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
19 GLOBAL METABOLOMICS SERVICES MARKET , COMPANY PROFILE
19.1 OVERVIEW
19.1.1 CREATIVE PROTEOMICS
19.1.1.1. COMPANY OVERVIEW
19.1.1.2. REVENUE ANALYSIS
19.1.1.3. GEOGRAPHIC PRESENCE
19.1.1.4. SERVICE PORTFOLIO
19.1.1.5. RECENT DEVELOPMENTS
19.1.2 AFEKTA TECHNOLOGIES
19.1.2.1. COMPANY OVERVIEW
19.1.2.2. REVENUE ANALYSIS
19.1.2.3. GEOGRAPHIC PRESENCE
19.1.2.4. PRODUCT PORTFOLIO
19.1.2.5. RECENT DEVELOPMENTS
19.1.3 BGI
19.1.3.1. COMPANY OVERVIEW
19.1.3.2. REVENUE ANALYSIS
19.1.3.3. GEOGRAPHIC PRESENCE
19.1.3.4. SERVICE PORTFOLIO
19.1.3.5. RECENT DEVELOPMENTS
19.1.4 ALBERT EINSTEIN COLLEGE OF MEDICINE
19.1.4.1. COMPANY OVERVIEW
19.1.4.2. REVENUE ANALYSIS
19.1.4.3. GEOGRAPHIC PRESENCE
19.1.4.4. SERVICE PORTFOLIO
19.1.4.5. RECENT DEVELOPMENTS
19.1.5 ANALYTICA LABORATORIES
19.1.5.1. COMPANY OVERVIEW
19.1.5.2. REVENUE ANALYSIS
19.1.5.3. GEOGRAPHIC PRESENCE
19.1.5.4. PRODUCT PORTFOLIO
19.1.5.5. RECENT DEVELOPMENTS
19.1.6 ANTI-DOPING LAB QATAR
19.1.6.1. COMPANY OVERVIEW
19.1.6.2. REVENUE ANALYSIS
19.1.6.3. GEOGRAPHIC PRESENCE
19.1.6.4. SERVICE PORTFOLIO
19.1.6.5. RECENT DEVELOPMENTS
19.1.7 THE METABOLOMICS INNOVATION CENTRE (TMIC)
19.1.7.1. COMPANY OVERVIEW
19.1.7.2. REVENUE ANALYSIS
19.1.7.3. GEOGRAPHIC PRESENCE
19.1.7.4. SERVICE PORTFOLIO
19.1.7.5. RECENT DEVELOPMENTS
19.1.8 SAPIENT
19.1.8.1. COMPANY OVERVIEW
19.1.8.2. REVENUE ANALYSIS
19.1.8.3. GEOGRAPHIC PRESENCE
19.1.8.4. SERVICE PORTFOLIO
19.1.8.5. RECENT DEVELOPMENTS
19.1.9 EVOTEC
19.1.9.1. COMPANY OVERVIEW
19.1.9.2. REVENUE ANALYSIS
19.1.9.3. GEOGRAPHIC PRESENCE
19.1.9.4. SERVICE PORTFOLIO
19.1.9.5. RECENT DEVELOPMENTS
19.1.10 HUMAN METABOLOME TECHNOLOGIES AMERICA, INC.
19.1.10.1. COMPANY OVERVIEW
19.1.10.2. REVENUE ANALYSIS
19.1.10.3. GEOGRAPHIC PRESENCE
19.1.10.4. SERVICE PORTFOLIO
19.1.10.5. RECENT DEVELOPMENTS
19.1.11 METWARE BIOTECHNOLOGY INC
19.1.11.1. COMPANY OVERVIEW
19.1.11.2. REVENUE ANALYSIS
19.1.11.3. GEOGRAPHIC PRESENCE
19.1.11.4. SERVICE PORTFOLIO
19.1.11.5. RECENT DEVELOPMENTS
19.1.12 METABOLON, INC.
19.1.12.1. COMPANY OVERVIEW
19.1.12.2. REVENUE ANALYSIS
19.1.12.3. GEOGRAPHIC PRESENCE
19.1.12.4. SERVICE PORTFOLIO
19.1.12.5. RECENT DEVELOPMENTS
19.1.13 VIENNA BIOCENTER
19.1.13.1. COMPANY OVERVIEW
19.1.13.2. REVENUE ANALYSIS
19.1.13.3. GEOGRAPHIC PRESENCE
19.1.13.4. SERVICE PORTFOLIO
19.1.13.5. RECENT DEVELOPMENTS
19.1.14 PANOMIX
19.1.14.1. COMPANY OVERVIEW
19.1.14.2. REVENUE ANALYSIS
19.1.14.3. GEOGRAPHIC PRESENCE
19.1.14.4. SERVICE PORTFOLIO
19.1.14.5. RECENT DEVELOPMENTS
19.1.15 BIOCRATES
19.1.15.1. COMPANY OVERVIEW
19.1.15.2. REVENUE ANALYSIS
19.1.15.3. GEOGRAPHIC PRESENCE
19.1.15.4. SERVICE PORTFOLIO
19.1.15.5. RECENT DEVELOPMENTS
19.1.16 SCIEX
19.1.16.1. COMPANY OVERVIEW
19.1.16.2. REVENUE ANALYSIS
19.1.16.3. GEOGRAPHIC PRESENCE
19.1.16.4. SERVICE PORTFOLIO
19.1.16.5. RECENT DEVELOPMENTS
19.1.17 EMERY PHARMA
19.1.17.1. COMPANY OVERVIEW
19.1.17.2. REVENUE ANALYSIS
19.1.17.3. GEOGRAPHIC PRESENCE
19.1.17.4. SERVICE PORTFOLIO
19.1.17.5. RECENT DEVELOPMENTS
19.1.18 CHARLES RIVER LABORATORIES
19.1.18.1. COMPANY OVERVIEW
19.1.18.2. REVENUE ANALYSIS
19.1.18.3. GEOGRAPHIC PRESENCE
19.1.18.4. SERVICE PORTFOLIO
19.1.18.5. RECENT DEVELOPMENTS
19.1.19 COSMOSID
19.1.19.1. COMPANY OVERVIEW
19.1.19.2. REVENUE ANALYSIS
19.1.19.3. GEOGRAPHIC PRESENCE
19.1.19.4. SERVICE PORTFOLIO
19.1.19.5. RECENT DEVELOPMENTS
19.1.20 THE PHILIPPINE GENOME CENTER
19.1.20.1. COMPANY OVERVIEW
19.1.20.2. REVENUE ANALYSIS
19.1.20.3. GEOGRAPHIC PRESENCE
19.1.20.4. SERVICE PORTFOLIO
19.1.20.5. RECENT DEVELOPMENTS
19.1.21 GENETIKA SCIENCE
19.1.21.1. COMPANY OVERVIEW
19.1.21.2. REVENUE ANALYSIS
19.1.21.3. GEOGRAPHIC PRESENCE
19.1.21.4. SERVICE PORTFOLIO
19.1.21.5. RECENT DEVELOPMENTS
19.1.22 OWL METABOLOMICS
19.1.22.1. COMPANY OVERVIEW
19.1.22.2. REVENUE ANALYSIS
19.1.22.3. GEOGRAPHIC PRESENCE
19.1.22.4. SERVICE PORTFOLIO
19.1.22.5. RECENT DEVELOPMENTS
19.1.23 WEST COAST METABOLOMICS CENTER
19.1.23.1. COMPANY OVERVIEW
19.1.23.2. REVENUE ANALYSIS
19.1.23.3. GEOGRAPHIC PRESENCE
19.1.23.4. SERVICE PORTFOLIO
19.1.23.5. RECENT DEVELOPMENTS
19.1.24 STEMINA BIOMARKER DISCOVERY, INC.
19.1.24.1. COMPANY OVERVIEW
19.1.24.2. REVENUE ANALYSIS
19.1.24.3. GEOGRAPHIC PRESENCE
19.1.24.4. SERVICE PORTFOLIO
19.1.24.5. RECENT DEVELOPMENTS
19.1.25 CHENOMX INC.
19.1.25.1. COMPANY OVERVIEW
19.1.25.2. REVENUE ANALYSIS
19.1.25.3. GEOGRAPHIC PRESENCE
19.1.25.4. SERVICE PORTFOLIO
19.1.25.5. RECENT DEVELOPMENTS
19.1.26 METAWARE BIO
19.1.26.1. COMPANY OVERVIEW
19.1.26.2. REVENUE ANALYSIS
19.1.26.3. GEOGRAPHIC PRESENCE
19.1.26.4. SERVICE PORTFOLIO
19.1.26.5. RECENT DEVELOPMENTS
19.1.27 LIPOTYPE
19.1.27.1. COMPANY OVERVIEW
19.1.27.2. REVENUE ANALYSIS
19.1.27.3. GEOGRAPHIC PRESENCE
19.1.27.4. SERVICE PORTFOLIO
19.1.27.5. RECENT DEVELOPMENTS
19.1.28 CAYMANCHEM
19.1.28.1. COMPANY OVERVIEW
19.1.28.2. REVENUE ANALYSIS
19.1.28.3. GEOGRAPHIC PRESENCE
19.1.28.4. SERVICE PORTFOLIO
19.1.28.5. RECENT DEVELOPMENTS
19.1.29 SEGAL CANCER PROTEOMICS CENTRE
19.1.29.1. COMPANY OVERVIEW
19.1.29.2. REVENUE ANALYSIS
19.1.29.3. GEOGRAPHIC PRESENCE
19.1.29.4. SERVICE PORTFOLIO
19.1.29.5. RECENT DEVELOPMENTS
19.1.30 SWEDISH METABOLOMICS CENTRE
19.1.30.1. COMPANY OVERVIEW
19.1.30.2. REVENUE ANALYSIS
19.1.30.3. GEOGRAPHIC PRESENCE
19.1.30.4. SERVICE PORTFOLIO
19.1.30.5. RECENT DEVELOPMENTS
20 RELATED REPORTS
21 CONCLUSION
22 QUESTIONNAIRE
23 ABOUT DATA BRIDGE MARKET RESEARCH
